Amgen Inc ((AMGN)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. and AstraZeneca have initiated a Phase 3 clinical study titled ‘A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)’. The study aims to evaluate the efficacy of adding tarlatamab to the existing treatment regimen of durvalumab, carboplatin, and etoposide, with a focus on improving overall survival rates in patients with untreated extensive stage small-cell lung cancer.
The study involves two groups: one receiving the experimental combination of tarlatamab, durvalumab, carboplatin, and etoposide, and the other receiving the standard treatment of durvalumab, carboplatin, and etoposide. All drugs are administered via intravenous infusion.
This interventional study is randomized with a parallel assignment model and no masking, primarily aiming to treat the condition. The study began on August 18, 2025, with the latest update submitted on August 21, 2025, indicating the study is actively recruiting participants.
The initiation of this study could potentially influence the stock performance of Amgen and AstraZeneca, as positive outcomes may enhance their competitive positioning in the oncology market. Investors should monitor this development closely, considering the broader industry context and competitor activities.
The study is ongoing, with further details available on the ClinicalTrials portal.